252 related articles for article (PubMed ID: 30047610)
21. Inhibitory effects of icotinib combined with antiangiogenic drugs in human non-small cell lung cancer xenograft models are better than single target drugs.
Jiang P; Zhang Y; Cui J; Wang X; Li Y
Thorac Cancer; 2022 Jan; 13(2):257-264. PubMed ID: 34855286
[TBL] [Abstract][Full Text] [Related]
22. Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo.
Hu X; Shi S; Wang H; Yu X; Wang Q; Jiang S; Ju D; Ye L; Feng M
Sci Rep; 2017 Jul; 7(1):4559. PubMed ID: 28676644
[TBL] [Abstract][Full Text] [Related]
23. Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.
Wang T; Liu Y; Zhou B; Hao S; Wang Z; Liang N; Liu J; Wang S
Indian J Cancer; 2017; 54(1):215-222. PubMed ID: 29199694
[TBL] [Abstract][Full Text] [Related]
24. Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines
Feng X; Zhang Y; Li T; Li Y
Oncotarget; 2017 Dec; 8(69):114292-114299. PubMed ID: 29371987
[TBL] [Abstract][Full Text] [Related]
25. 20(S)-ginsenoside Rg3 sensitizes human non-small cell lung cancer cells to icotinib through inhibition of autophagy.
Wang XJ; Zhou RJ; Zhang N; Jing Z
Eur J Pharmacol; 2019 May; 850():141-149. PubMed ID: 30772396
[TBL] [Abstract][Full Text] [Related]
26. Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.
Yang G; Yao Y; Zhou J; Zhao Q
Oncol Rep; 2012 Jun; 27(6):2066-72. PubMed ID: 22446631
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an
Guan Y; Song Z; Li Y; Guo H; Shi J; Zhang X; Yao M
Oncologist; 2019 Aug; 24(8):1027-1030. PubMed ID: 31064887
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors.
Jiang Z; Zhang Y; Yang Y; Yue Z; Pan Z
Thorac Cancer; 2018 Sep; 9(9):1151-1155. PubMed ID: 30027579
[TBL] [Abstract][Full Text] [Related]
29. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.
Tan F; Shen X; Wang D; Xie G; Zhang X; Ding L; Hu Y; He W; Wang Y; Wang Y
Lung Cancer; 2012 May; 76(2):177-82. PubMed ID: 22112293
[TBL] [Abstract][Full Text] [Related]
30. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and preliminary evaluation of
Lu X; Wang C; Li X; Gu P; Jia L; Zhang L
Bioorg Med Chem; 2019 Feb; 27(3):545-551. PubMed ID: 30611635
[TBL] [Abstract][Full Text] [Related]
32. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
[TBL] [Abstract][Full Text] [Related]
33. Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations.
Heng W; You C; Shangli C; Chuang Q; Mingzhe X
Lung Cancer; 2019 Oct; 136():153-155. PubMed ID: 31422893
[No Abstract] [Full Text] [Related]
34. Synergistic inhibitory effect of berberine and icotinib on non-small cell lung cancer cells via inducing autophagic cell death and apoptosis.
Chen P; Dai CH; Shi ZH; Wang Y; Wu JN; Chen K; Su JY; Li J
Apoptosis; 2021 Dec; 26(11-12):639-656. PubMed ID: 34743246
[TBL] [Abstract][Full Text] [Related]
35. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J
Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808
[TBL] [Abstract][Full Text] [Related]
36. Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.
Nagai H; Yasuda H; Hatachi Y; Xue D; Sasaki T; Yamaya M; Sakamori Y; Togashi Y; Masago K; Ito I; Kim YH; Mio T; Mishima M
Int J Oncol; 2012 Jul; 41(1):24-30. PubMed ID: 22552400
[TBL] [Abstract][Full Text] [Related]
37. Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
Monica V; Lo Iacono M; Bracco E; Busso S; Di Blasio L; Primo L; Peracino B; Papotti M; Scagliotti G
Oncotarget; 2016 Nov; 7(47):76577-76589. PubMed ID: 27391433
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.
Zhao X; Zhu G; Chen H; Yang P; Li F; Du N
J Cancer Res Ther; 2014 Nov; 10 Suppl():C155-9. PubMed ID: 25450275
[TBL] [Abstract][Full Text] [Related]
39. Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling.
Gao Z; Chen W; Zhang X; Cai P; Fang X; Xu Q; Sun Y; Gu Y
Biomed Pharmacother; 2013 Jun; 67(5):351-6. PubMed ID: 23602321
[TBL] [Abstract][Full Text] [Related]
40. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Murata Y; Kusumoto S; Ando K; Ishida H; Ohnishi T; Sasaki Y
Mol Cancer Res; 2017 Jul; 15(7):915-928. PubMed ID: 28289161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
